Cited by 32Angiogenesis and VEGF in CancerEndometrial and Cervical Cancer TreatmentsOvarian cancer diagnosis and treatment

pRb2/p130 and VEGF expression in endometrial carcinoma in relation to angiogenesis and histopathologic tumor grade

Open access
Sanseverino, Francesca, Santopietro, Rosa, Torricelli, Michela, D'Andrilli, Giuseppina, Russo, Giuseppe, Cevenini, Gabriele, Bovicelli, Alessandro, Leoncini, Lorenzo +4 more·2006·Cancer Biology & Therapy

Abstract

PURPOSE: Endometrial cancer is the most common gynecologic malignancy. Established prognostic factors are histologic grade, depth of myometrial invasion, and extrauterine spread including retroperitoneal lymph node metastases. Tumorigenesis is a multistep process involving different genetic changes resulting in uncontrolled cellular proliferation, inhibition of apoptosis, and enhanced vascular proliferation among other events. Angiogenesis, the formation of new blood vessels from a preexisting vascular network, is necessary for invasive tumor growth and metastasis and constitutes an important point in the control of cancer progression. The pathogenesis of the angiogenetic phenotype may involve the inactivation of different tumor suppressor genes. EXPERIMENTAL DESIGN: We investigated the relationship between the expression levels of VEGF and the retinoblastoma family member pRb2/p130 in endometrial carcinoma in relation to histopathologic tumor grade in a cohort of 50 patients. RESULTS: We found that VEGF and pRB2/p130 expression were inversely correlated. Additionally, high grade tumors presented a significantly lower number of cells expressing pRb2/p130 when compared to low grade tumors. A significant positive correlation was found, by means of the Spearman coefficient, between VEGF expression and binary grading (0.450, p-value < 0.005) which is an architectural grading system that uses low-magnification assessment of amount of solid growth, pattern of invasion, and presence of necrosis to divide endometrioid carcinomas into low- and high-grade tumors. Additionally, we also found a negative correlation between pRb2/p130 expression levels and binary grading (-0.595, p-value < 0.005). Interestingly, we also found that VEGF and pRb2/p130 expression levels were not related to staging (p-value > 0.005). CONCLUSIONS: These results open up a new perspective including novel markers that, combined together, may be useful in patient screening for endometrial cancer aggressiveness.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4161/cbt.5.1.2345

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Altered RB expression correlates with higher grade, poorly differentiated gastrointestinal cancers.

    “Altered RB expression has been observed to be correlated with higher grade, poorly differentiated gastrointestinal cancers99.”
  • Changes in RB expression are significantly associated with invasion and metastasis in oesophageal cancers.

    “Altered RB expression patterns have been observed in poorly differentiated, metastatic hepatocellular carcinomas137, and correlative analyses have suggested that changes in RB expression are significantly associated with invasion and metastasis of oesophageal cancers99.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 4

  1. Ayhan A, Celik H, Coskun F, Baykal C, Salman MC, Aksan G. Restaging in gynaecolog- ical cancers. Eur J Gynaecol Oncol 2005; 26:25-30.
  2. In: Creasman WT, ed. Announcements: FIGO stages-1988 revision. Gynecol Oncol 1989; 35:125-127.
  3. Mittal KR, Schwartz PE, Barwick KW. Architectural (FIGO) grading, nuclear grading, and other prognostic indicators in stage I endometrial adenocarcinoma with identification of high-risk and low-risk groups. Cancer 1988; 61:538-45.
  4. Christopherson WM, Connelly PJ, Alberhasky RC. Carcinoma of the endometrium. V. An analysis of prognosticators in patients with favorable subtypes and Stage I disease. Cancer 1983; 51:1705-9.

Cited by

Sorted by citations

Authors
Sanseverino, F., Santopietro, R., Torricelli, M., D'Andrilli, G., Russo, G., Cevenini, G., Bovicelli, A., Leoncini, L., Scambia, G., Petraglia, F., Claudio, P. P., & Giordano, A.
Affiliations
  • University of Siena (IT)
  • Temple University (US)
  • Università Cattolica del Sacro Cuore (IT)
Corresponding author
Giordano, Antonio
Venue
Cancer Biology & Therapy
Published
2006-01-16
Volume
5
Issue
1
Pages
84-88
ISSN
  • 1538-4047 (ISSN-L)
  • 1555-8576
OpenAlex
W2069011214
Cited by
32
References
26
Citations by year
2025: 1 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2016: 3 · 2015: 3 · 2014: 2 · 2013: 2 · 2012: 1
FWCI
1.22
Type
journal article
Language
en
Open access
Locations
  • Cancer Biology & Therapy (publishedVersion)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
  • Florence Research (University of Florence) (submittedVersion)
  • Use Siena air (University of Siena) (submittedVersion)
  • INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Funders
  • Associazione Italiana per la Ricerca sul Cancro
  • National Institutes of Health
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
Keywords
endometrial cancer, vascular endothelial growth factor, tumor angiogenesis, tumor suppressor, prognostic factors, endometrioid carcinoma, tumor aggressiveness
MeSH terms
Female, Humans, Neoplasm Staging, Prognosis, Biomarkers, Tumor, Endometrial Neoplasms, Carcinoma, Endometrioid, Vascular Endothelial Growth Factor A, Retinoblastoma-Like Protein p130

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review